FALMINA
Clinical safety rating
cautionComprehensive clinical and safety monograph for FALMINA (FALMINA).
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
| Metabolism | Hepatic via CYP2D6; active metabolite norfluoxetine; elimination half-life 4-6 days (fluoxetine), 4-16 days (norfluoxetine). |
| Excretion | Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%. |
| Half-life | Terminal elimination half-life 12-15 hours; in severe renal impairment (CrCl <30 mL/min) extends to 30-40 hours, requiring dose adjustment. |
| Protein binding | 98% bound to albumin. |
| Volume of Distribution | 0.2-0.3 L/kg, reflecting confinement to plasma and interstitial space; minimal tissue penetration. |
| Bioavailability | Oral: 75-85% due to moderate first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours. Duration may be prolonged in hepatic impairment due to reduced clearance. |
| Molecular Weight | 350.42 |
| Action Class | Combination oral contraceptive (estrogen-progestin) |
FALMINA (fictitious drug): 500 mg orally every 12 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 500 mg every 24 hours. GFR 15-29 mL/min: 250 mg every 24 hours. GFR <15 mL/min: 125 mg every 24 hours. Hemodialysis: 125 mg post-dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use with caution; 250 mg every 24 hours. |
| Pediatric use | 5 mg/kg/dose orally every 12 hours; maximum 500 mg/dose. |
| Geriatric use | Initiate at 250 mg orally every 12 hours; titrate to renal function. |
| 1st trimester | Avoid; known teratogen in animal studies; human data limited. |
| 2nd trimester | Avoid; potential fetal harm. |
| 3rd trimester | Avoid; risk of neonatal complications. |
Clinical note
Comprehensive clinical and safety monograph for FALMINA (FALMINA).
| Placental transfer | Crosses placenta readily; fetal concentrations comparable to maternal. |
| Breastfeeding | Excreted in breast milk; avoid breastfeeding due to potential adverse effects in infant. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malformations in exposed fetuses based on epidemiological studies, but use is not recommended due to lack of need. Second and third trimesters: associated with increased risk of fetal harm including congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, preterm birth) from continued exposure. Risk of fetal feminization from progestin component in late pregnancy. |
| Fetal Monitoring | Monitor for signs of thrombosis (DVT, PE), hypertension, liver dysfunction, and mood changes. In pregnancy, discontinue immediately if pregnancy is suspected or confirmed. Perform pregnancy test prior to initiation. During use, monitor blood pressure, liver function, and screen for VTE risk factors. If VTE occurs, discontinue and manage appropriately. |
| Fertility Effects | Falmina suppresses ovulation, thus prevents fertility during use. Fertility returns to baseline after discontinuation; no permanent effects on fertility have been observed. No adverse effects on subsequent pregnancy outcomes or oocyte quality. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Common Effects | Nausea, Vomiting, Headache, Breast tenderness, Breakthrough bleeding, Spotting, Weight changes, Mood changes, Acne, Fluid retention |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebral hemorrhage, Retinal thrombosis |
Hypersensitivity to FalminaPregnancyLactationSevere hepatic impairment
| Precautions | Serotonin syndrome; discontinuation syndrome; hyponatremia; bleeding risk; mania/hypomania; seizures; angle-closure glaucoma; QT prolongation (overdose). |
| Food/Dietary | Avoid high-sodium foods as they can counteract the diuretic effect. Limit licorice intake (glycyrrhizin) which can worsen hypokalemia. Grapefruit juice may increase absorption; avoid large amounts. Maintain adequate fluid intake unless fluid restriction is advised. |
| Clinical Pearls | FALMINA is a high-ceiling loop diuretic used for edema and hypertension. Monitor serum potassium and magnesium regularly; risk of hypokalemia and hypomagnesemia. Ototoxicity is dose-dependent and more common with rapid IV administration or concurrent use of other ototoxic drugs. Onset of action: oral 30-60 min, IV 5 min. Duration: oral 6-8 hr, IV 2 hr. Avoid in anuria, hepatic coma, severe electrolyte depletion. |
| Patient Advice | Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Report any hearing loss, ringing in ears, or dizziness immediately, especially if on high doses or other ototoxic drugs. · Weigh yourself daily and notify your doctor if you gain more than 2-3 pounds in 24 hours or lose weight too quickly. · Avoid sudden position changes to prevent dizziness; rise slowly from sitting or lying down. · Limit alcohol intake as it may worsen dizziness and low blood pressure. · This drug may increase blood sugar; monitor glucose if diabetic. · Do not take with NSAIDs (e.g., ibuprofen, aspirin) unless approved by your doctor as they may reduce effectiveness and increase kidney risk. |
Loading safety data…